BRAF V600EPhase 3 RCT (updated)JCO 2021來源:人工整理
EC doublet vs triplet vs control
關鍵結果EC mOS 9.3 mo, HR 0.61; triplet = doublet
確認 doublet 即夠——加 binimetinib 無額外獲益。FDA/EMA 核准 EC doublet
詳細證據整理
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Abstract
PURPOSE: BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival (OS) and objective response rate (ORR; by blinded central review) versus standard of care. The purpose of this analysis was to report updated efficacy and safety data.
METHODS: In this open-label, phase III trial, 665 patients with BRAF V600E–mutant mCRC were randomly assigned 1:1:1 to receive triplet, doublet, or control. Primary end points were OS and independently reviewed ORR comparing triplet to control. OS for doublet versus control was a key secondary end point. Updated analyses include 6 months of additional follow-up and ORR for all randomized patients.
RESULTS: Patients received triplet (n = 224), doublet (n = 220), or control (n = 221). Median OS was 9.3 months (95% CI, 8.2 to 10.8) for triplet and 5.9 months (95% CI, 5.1 to 7.1) for control (hazard ratio [HR], 0.60 [95% CI, 0.47 to 0.75]). Median OS for doublet was 9.3 months (95% CI, 8.0 to 11.3) (HR vs control, 0.61 [95% CI, 0.48 to 0.77]). Confirmed ORR was 26.8% (95% CI, 21.1% to 33.1%) for triplet, 19.5% (95% CI, 14.5% to 25.4%) for doublet, and 1.8% (95% CI, 0.5% to 4.6%) for control. Adverse events were consistent with the prior primary analysis, with grade ≥3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet, and control, respectively.
CONCLUSION: In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the metastatic setting compared with standard chemotherapy. Based on the primary and updated analyses, encorafenib plus cetuximab is a new standard care regimen for previously treated patients with BRAF V600E mCRC.
Introduction
Mutations in BRAF are recurrently detected in human cancer, including melanoma, colorectal, thyroid, non–small-cell lung, and hairy cell leukemia. BRAF encodes a serine/threonine protein kinase that is part of the RAS/RAF/MEK/ERK pathway. The majority of mutations in BRAF result in V600E substitution, and these patients generally have a poor prognosis. Approximately 10% of patients with metastatic colorectal cancer (mCRC) have a BRAF mutation, with recent estimates ranging from as low as 5% to as high as 21%. BRAF V600E mutation results in downstream phosphorylation of MEK and ERK, leading to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which drives tumor cell proliferation and survival.
New therapeutic strategies for the BRAF V600E–mutant mCRC population are warranted as standard cytotoxic combinations result in a modest benefit in the first-line setting and limited benefits in the second-line and beyond. BRAF inhibitor monotherapy in BRAF-mutant mCRC has low response rates. Suboptimal response to BRAF inhibitor monotherapy is linked to incomplete inhibition of MAPK signaling in CRC cell lines. BRAF inhibition results in a rapid release of feedback-suppressed epidermal growth factor receptor (EGFR)–mediated MAPK signaling in in vitro studies of BRAF V600E–mutant CRC cells, leading to a rebound in MAPK activation and continued cell proliferation. BRAF and EGFR inhibitor combinations result in synergistic inhibition of tumor growth in BRAF V600E–mutant CRC xenograft models, and subsequent clinical studies of EGFR-targeted monoclonal antibodies combined with BRAF inhibition suggested improved activity compared with single-agent BRAF inhibitors. The addition of a MEK inhibitor to BRAF inhibition has also been found to increase the inhibition of the MAPK pathway and produce potentially greater antitumor activity in preclinical and clinical studies.
Encorafenib is a BRAF inhibitor with prolonged pharmacodynamic activity compared with other available BRAF inhibitors. The doublet combination of the BRAF inhibitor encorafenib and the anti-EGFR monoclonal antibody cetuximab showed promise in early clinical trials. The BEACON CRC study evaluated whether the combination of encorafenib plus cetuximab with or without the MEK inhibitor binimetinib could improve overall survival (OS) compared with standard therapy in patients with BRAF V600E–mutated mCRC whose disease has progressed after one or two prior lines of therapy. The study was a randomized, three-arm, phase III study that evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan plus cetuximab or FOLFIRI (folinic acid, fluorouracil, and irinotecan) plus cetuximab in 665 patients with BRAF V600E–mutant mCRC whose disease had progressed after one or two prior regimens. In a prespecified analysis, encorafenib plus cetuximab with or without binimetinib significantly improved OS and objective response rate (ORR) in patients with BRAF V600E mCRC compared with current standard of care. This study marked the first evidence of survival benefit for a chemotherapy-free targeted treatment regimen in prospectively biomarker-defined patients with mCRC, defining a new standard of care for patients with previously treated BRAF V600E mCRC. Herein, we report updated post hoc efficacy and safety results as well as exploratory subgroup analyses of the BEACON CRC trial.
Methods
Study Design and Participants
The BEACON CRC study is a global, multicenter, randomized, open-label, phase III trial comparing encorafenib (300 mg once a day) plus binimetinib (45 mg twice a day) plus cetuximab (400 mg/m² initial dose and then 250 mg/m² once a week) (ENCO/BINI/CETUX or triplet combination), encorafenib plus cetuximab (ENCO/CETUX or doublet combination), with the control arm of investigators' choice of either cetuximab combined with irinotecan alone (180 mg/m² on days 1 and 15) or cetuximab combined with FOLFIRI. Eligible patients were randomly assigned in a 1:1:1 ratio and stratified by ECOG performance status (0/1), prior use of irinotecan (yes/no), and cetuximab formulation (United States–licensed/European Union–approved).
Patients with histologically or cytologically confirmed mCRC with centrally confirmed BRAF V600E mutation and progression after one or two prior treatment regimens for metastatic disease were eligible for this trial. Prior BRAF, MEK, or EGFR inhibitors were not permitted.
Study End Points
The primary end points of the trial were OS for the triplet combination compared with the control and ORR (by blinded independent central review) for the triplet combination compared with the control. OS for the doublet arm compared with the control arm was defined as a key secondary end point. Other secondary end points included progression-free survival (PFS), duration of response (DOR; defined as time from first radiographic evidence of response to the earliest documented disease progression or death due to any cause), safety, and a comparison of ORR and OS between the doublet and triplet arms.
Tumor assessments were performed according to RECIST v1.1 prior to random assignment and every 6 weeks from the date of random assignment for the first 24 weeks of treatment and then every 12 weeks thereafter until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, patient lost to follow-up, or death, regardless of whether study treatment had been discontinued.
Statistical Analysis
An updated analysis was conducted after an additional 6 months of follow-up relative to the primary analysis (February 11, 2019) with a data cutoff of August 15, 2019. Time-to-event end points and ORR were analyzed based on all randomly assigned patients (ie, intention to treat population). Safety was evaluated by assessments of adverse events and laboratory abnormalities in patients who received at least one dose of trial drug and had at least one post-treatment safety assessment. Results of this post hoc analysis are descriptive with no formal hypothesis tests conducted. The study was not powered to formally compare the results of the triplet combination with the doublet combination.
Results
Patients
A total of 665 patients were enrolled from May 2017 to January 2019 and were randomly assigned to receive the triplet combination (n = 224), doublet combination (n = 220), or one of the control regimens (n = 221). At the time of the data cutoff date for the current report, 13.4% of patients in the triplet arm, 13.6% in the doublet arm, and 3.2% in the control arm were receiving study treatment. Overall, baseline demographic and clinical characteristics were generally similar in the three randomized phase III treatment arms, although there were trends to higher multiorgan involvement, elevated carcinoembryonic antigen (> 5 μg/L), and C-reactive protein (CRP) > 10 mg/L in the triplet arm.
Efficacy
The median duration of follow-up for survival was 12.8 months across the arms as of the data cutoff date for this analysis (August 15, 2019).
Overall Survival: The triplet combination resulted in a median OS of 9.3 months (95% CI, 8.2 to 10.8) compared with 5.9 months (95% CI, 5.1 to 7.1) for the control group, with a 40% reduction in the hazard of death (HR of 0.60; 95% CI, 0.47 to 0.75). Similarly, the doublet combination resulted in a median OS of 9.3 months (95% CI, 8.0 to 11.3), with a 39% reduction in the risk of death compared with control (HR of 0.61; 95% CI, 0.48 to 0.77). The OS results were similar between triplet and doublet with a HR of 0.95 (95% CI, 0.74 to 1.21).
| Endpoint | Triplet (n=224) | Doublet (n=220) | Control (n=221) |
|---|---|---|---|
| Median OS | 9.3 mo (95% CI 8.2-10.8) | 9.3 mo (95% CI 8.0-11.3) | 5.9 mo (95% CI 5.1-7.1) |
| OS HR vs Control | 0.60 (95% CI 0.47-0.75) | 0.61 (95% CI 0.48-0.77) | -- |
| Confirmed ORR | 26.8% (95% CI 21.1-33.1) | 19.5% (95% CI 14.5-25.4) | 1.8% (95% CI 0.5-4.6) |
| Median PFS | 4.5 mo (95% CI 4.2-5.4) | 4.3 mo (95% CI 4.1-5.4) | 1.5 mo (95% CI 1.5-1.9) |
| PFS HR vs Control | 0.42 (95% CI 0.33-0.53) | 0.44 (95% CI 0.35-0.55) | -- |
| Median DOR | 4.4 mo | 5.5 mo | 5.5 mo |
| Grade ≥3 AEs | 65.8% | 57.4% | 64.2% |
Subgroup Analyses: The results for subgroups were generally consistent with the overall analysis. Both triplet and doublet showed improved OS compared with control in all subgroups. The triplet group compared with doublet showed potential benefit in patients with high baseline levels of CRP (HR, 0.76), ECOG performance status of 1 (HR, 0.81), incompletely resected primary tumor (HR, 0.80), and ≥3 organ involvement (HR, 0.69).
Response Rates by Prior Lines: For patients with only 1 prior line of therapy, response rates were 28% for triplet, 20% for doublet, and 2% for control. For patients with more than one prior line, response rates were 24% for triplet, 19% for doublet, and 1% for control.
Progression-Free Survival: Both the triplet and doublet combinations prolonged PFS by blinded independent central review relative to the control arm; median PFS was 4.5 months (95% CI, 4.2 to 5.4), 4.3 months (95% CI, 4.1 to 5.4), and 1.5 months (95% CI, 1.5 to 1.9) for triplet, doublet, and control, respectively, with HRs of 0.42 (95% CI, 0.33 to 0.53) for triplet versus control and 0.44 (95% CI, 0.35 to 0.55) for doublet versus control.
Safety
Safety results for the triplet and doublet arms relative to the control arm are consistent with the primary analysis and show no new safety signals. The median duration of exposure to study drugs was 21 weeks in the triplet arm, 19 weeks in the doublet arm, and 7 weeks in the control arm.
The most frequently reported adverse events (all grades) in the triplet arm were diarrhea (66.2%), dermatitis acneiform (50.0%), nausea (48.2%), anemia (45.9%), vomiting (44.1%), abdominal pain (34.2%), fatigue (33.3%), decreased appetite (29.7%), constipation (28.4%), and asthenia (27.9%). In the doublet arm, the most frequently reported adverse events were diarrhea (38.4%), nausea (38.0%), fatigue (33.3%), decreased appetite (31.0%), and dermatitis acneiform (30.1%). In the control arm, the most frequently reported adverse events were diarrhea (48.7%), nausea (43.5%), dermatitis acneiform (39.9%), vomiting (31.6%), decreased appetite (29.0%), fatigue (28.0%), abdominal pain (28.0%), and asthenia (27.5%).
Dermatitis acneiform, diarrhea, nausea, constipation, and vomiting were reported at a higher incidence (>10.0% difference) in the triplet arm than the doublet arm, whereas headache, arthralgia, and melanocytic nevus were reported at a higher incidence in the doublet arm than the triplet arm.
Grade 3 or greater adverse events were observed in 66%, 57%, and 64% of patients treated with the triplet, doublet, and control regimens, respectively. Discontinuation of all therapy primarily due to an adverse event was seen in 9% of patients in the triplet arm, 9% in the doublet arm, and 11% in the control arm. Deaths resulting from AEs occurred in 5%, 4%, and 4% of patients treated with the triplet, doublet, and control regimens, respectively.
Discussion
In these updated analyses of the phase III BEACON CRC study, the doublet encorafenib plus cetuximab regimen had similar overall efficacy to the triplet regimen, indicating that this regimen could be effectively used in patients with BRAF V600E–mutant mCRC whose disease had progressed after one or two prior regimens. Both the triplet and doublet regimens had an acceptable safety profile and significant clinically meaningful benefits relative to the control arm.
The study was not powered to compare the 2 experimental arms directly; however, the updated descriptive analyses comparing the triplet and doublet arms showed similar efficacy in the overall population across end points including OS and PFS. These results suggest that the doublet regimen is sufficient to maximize the OS benefit and is the optimal regimen for this patient population. The United States Food and Drug Administration approved the doublet for the treatment of BRAF V600E–mutant mCRC after prior therapy in April 2020.
Subgroup analyses suggested that patients with several poor prognostic indicators may benefit from the addition of binimetinib across primary and secondary end points, including patients with elevated CRP, ECOG performance status of 1, incompletely resected primary tumor, and ≥3 organ involvement.
In conclusion, these updated analyses confirmed that encorafenib plus cetuximab with or without binimetinib improved OS, ORR, and PFS in previously treated patients with BRAF V600E–mutant mCRC compared with standard chemotherapy. Encorafenib plus cetuximab thus had similar OS efficacy with or without binimetinib, indicating that encorafenib plus cetuximab could be effectively used as the new standard of care for previously treated patients with BRAF V600E–mutant mCRC.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…